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Summary
Atrial fibrillation (AF), the most common clinically
relevant arrhythmia, affects 2.2 million individuals
in the USA and 4.5 million in Europe, resulting in sig-
nificant morbidity and mortality. Pharmacotherapy
aimed at controlling both heart rate and rhythm is
employed to relieve AF symptoms, though debate
continues about which approach is preferable. AF
prevalence rises with age from 0.4% to 1% in the
general population to 11% in those aged >70 years.
AF is associated with a pro-thrombotic state and
other comorbidities; age, hypertension, heart failure
and diabetes mellitus all play a key role in AF patho-
genesis. Anti-coagulation is essential for stroke pre-
vention in patients with AF and is recommended for
patients with one or more risk factors for stroke.
Used within the recommended therapeutic range,
warfarin and other vitamin K antagonists decrease
the incidence of stroke and mortality in AF patients.
Warfarin remains under-used, however, because of
the perceived high risk of haemorrhage, narrow
therapeutic window and need for regular monitor-
ing. Several novel anti-coagulants show promise
in AF-related stroke prevention. In particular,
the novel, oral, direct thrombin inhibitor, dabigatran
etexilate, recently licensed by the US Food and
Drug Administration (FDA) and Health Canada has
shown improved efficacy and safety compared with
warfarin for stroke prevention in AF, and has the
potential to replace warfarin in this indication. The
increasing number of new therapeutic options,
including improved anti-arrhythmic agents, novel
anti-coagulants and more accessible ablation tech-
niques, are likely to deliver better care for AF
patients in the near future.
Introduction
Atrial fibrillation (AF) is the most common clinically
relevant arrhythmia seen in the USA and Europe,
found in 1–2% of the population and affecting an
estimated 2.2 million individuals in the USA and 4.5
million in Europe.
1,2 It is responsible for one-third of
hospitalizations for cardiac rhythm disturbances
2
and is associated with significant morbidity and
mortality, including a 4- to 5-fold increased risk of
stroke and a 3-fold increased risk of heart failure,
3
resulting in significant effects on quality of life (QoL)
and a high socioeconomic burden.
The primary goals of pharmacotherapy in AF are
to restore sinus rhythm, control heart rate and pre-
vent stroke. Anti-coagulation therapy is an essential
strategy in the prevention of stroke in AF patients.
Although warfarin and other vitamin K antagonists
(VKAs) decrease stroke incidence and mortality in
AF patients, warfarin is perceived to be associated
with a high risk of haemorrhage and is difficult to
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This review explores currently available AF thera-
pies and examines the evidence for newer treatment
options.
Diagnosis, epidemiology and burden
of AF
Diagnosis
Typical signs and symptoms of AF relate to irregular
heart rate and include palpitations, chest pain, short-
ness of breath, fainting and fatigue.
2 AF can be as-
ymptomatic, however, and is sometimes diagnosed
only after a stroke or transient ischaemic attack
(TIA). Diagnosis of AF involves investigation of the
aetiology and nature of the arrhythmia via patient
history, physical examination, electrocardiogram,
transthoracic echocardiogram and routine blood
tests; some patients also require coronary angiog-
raphy or magnetic tomography. Early diagnosis of
AF reduces mortality and morbidity,
4 and thus pro-
grammes to improve self-diagnosis, such as the
‘Know Your Pulse’ global campaign, are underway
in several countries.
5
The American College of Cardiology (ACC),
American Heart Association (AHA) and the
European Society of Cardiology (ESC) guidelines rec-
ommend classification of AF into three primary
types:
2 paroxysmal (recurrent episodes that self-
terminate in <7 days); persistent (non–self-
terminating recurrent episodes lasting >7 days that
can be converted to sinus rhythm by electrical or
pharmacological cardioversion); and permanent
(ongoing long-term AF resistant to electrical or
pharmacological cardioversion). Individuals may ex-
perience different types of AF at different times, and
it is therefore practical to categorize patients by their
most frequent presentation.
The recent (2010) ESC guidelines describe a con-
tinuum of AF, recognizing that the condition begins
with short, infrequent episodes and often progresses
to longer, more sustained and frequent attacks.
1 The
guidelines also acknowledges the fact that AF can
be asymptomatic. Five categories of AF are desc-
ribed: first diagnosed, paroxysmal (which usually re-
solves within 48h but may continue for up to
7 days), persistent (lasting >7 days or requiring car-
dioversion), long-standing persistent (lasting 51y e a r )
and permanent (accepted by the patient and phys-
ician, and not managed using rhythm control).
1
Guidelines also categorize AF relating to patient
characteristics.
2 Lone AF presents in the absence of
clinical or cardiographic findings of other cardiovas-
cular disease, usually in patients aged <60 years.
Valvular AF has heart valve disease as its leading
cause, while non-valvular AF presents in the ab-
sence of rheumatic mitral valve disease, mitral valve
repair or artificial heart valve. Secondary AF occurs
in the setting of other conditions such as acute myo-
cardial infarction, cardiac surgery, hyperthyroidism
or pneumonia.
Epidemiology
AF is associated with conditions such as hyperten-
sion, primary heart diseases, lung diseases, exces-
sive alcohol consumption
6 and hyperthyroidism.
Sufferers may also have a genetic susceptibility to
the condition.
7 Current evidence suggests that hyper-
tension and obesity play a key role in AF pathogen-
esis; inflammation may be a trigger to initiate AF.
8
AF prevalence is highly age-dependent, increas-
ing from 0.4–1% in the general population to 11%
in those aged >70 years, and around 17% in indi-
viduals aged 585 years.
2,9–11 However, with a
growing elderly population, AF prevalence is likely
to more than double during the next 50 years.
12
Stroke risk
The Framingham Study data indicate that AF is asso-
ciated with a pro-thrombotic state that increases
stroke risk 5-fold.
13 A thrombus, commonly formed
in the left atrial appendage, embolizes, travels in the
circulation and blocks a blood vessel in the brain.
2
Paroxysmal, persistent and permanent AF all appear
to confer the same risk of stroke.
14 The likelihood of
AF-related stroke varies among patients and is de-
pendent on several factors; increasing age is one of
the strongest risk factors.
Stroke risk is classified in several risk stratification
schemes including CHADS2, CHA2DS2-VASc, AF
Investigators, Framingham, Birmingham/National
Institute for Clinical Excellence [NICE] and ACC/
AHA/ESC based on multivariate analyses of study
cohorts or expert consensus.
15,16 These schemes
most frequently include features such as prior
stroke/TIA, patient age, hypertension and diabetes
mellitus; absolute stroke rates and patients categor-
ized as low risk or high risk can differ substantially
across the various schemes.
The CHADS2 score has been the most widely
used to measure AF stroke risk and to guide anti-
coagulant therapy choice. CHADS2 was developed
by the National Registry of AF, based on point allo-
cations for AF risk factors and has been validated in
a clinical trial involving more than 11000 subjects
17
(Table 1). For each 1-point increase in CHADS2,
stroke rate per 100 000 years without anti-
thrombotic therapy increases by a factor of 1.5
(Table 2). A CHADS2 validation study classified a
748 J. Kreuzerscore of 0–1 as low risk, 1–2 as moderate risk and
3–6 as high risk (Table 2). However, this system has
several limitations that may lead to over- or under-
estimation of stroke risk in AF. First, it does not ac-
count for every risk factor for stroke. Patients with a
history of stroke or TIA as their only risk factor have
a CHADS2 score of 2 indicating moderate risk, des-
pite having very high risk of recurrent stroke.
18 Age
>75 years does not confer a uniform single risk, as
shown by the AF Working Group study.
19 Finally,
well controlled hypertension may be less of a risk
than other CHADS2-defining factors, as stroke risk
only markedly rises with mean systolic blood pres-
sure >140mmHg in anti-coagulated patients.
20
CHADS2 scoring has been found to classify the
greatest proportion of patients as moderate risk com-
pared with other schemes, which can cause confu-
sion over appropriate treatments (aspirin vs. VKAs).
Thus, the ACC/AHA/ESC guidelines recommend that
the ‘selection of anti-thrombotic agent should be
based upon the absolute risks of stroke and bleed-
ing, and the relative risk and benefit for a given
patient’.
An improved stratification system (CHA2DS2-
VASc) includes new risk factors such as female
gender, vascular or heart disease, and age >65
years; it also considers both definitive and combin-
ation risk factors.
16 In this scheme, patients with no
risk factors are designated low risk; one combination
risk factor [heart failure/left ventricular ejection frac-
tion (LVEF) 440, hypertension, diabetes, vascular
disease, female gender, age 65–74 years] confers
intermediate risk; and previous stroke, TIA or embol-
ism, age 575 years or 52 combination risk factors
(heart failure/LVEF 440, hypertension, diabetes,
vascular disease, female gender, age 65–74 years)
confers high risk. The recent ESC guidelines recom-
mends that for individuals with a CHA2DS2-VASc
score of 1, 2 or above, oral anti-coagulant therapy
is desirable.
1 Aspirin therapy is now recommended
for very few patients who are at very low risk of
stroke.
The ESC 2010 guidelines specify that assess-
ment of bleeding risk before administration of anti-
coagulant therapy in AF should make use of the
HAS-BLED scoring system, which assigns one
point to the following risk factors. Hypertension,
Abnormal liver or renal function (1 point each),
Stroke, Bleeding history or disposition, Labile inter-
national normalized ratios, Elderly status (age
565 years) and Drug or alcohol use (1 point each);
high risk is defined by the scheme as 3 points or
higher.
1,21
Burden
AF-associated strokes are generally more severe than
strokes not associated with AF and are more likely
to be fatal,
22 with 50% of patients dying within
1 year in one population-based registry study.
23
The high morbidity associated with AF complica-
tions, especially stroke, has a significant impact on
QoL and healthcare resource utilization.
24 In a
retrospective analysis of three federally funded data-
bases, estimated total annual medical costs for AF
treatment in US inpatient, emergency room and
outpatient hospital settings were $US6.65 billion
(2005 expenditure).
25 Similarly, in 2000 the direct
costs of treating AF in the UK were estimated at
£459 million or 0.88% of total National Health
Service expenditure, via analysis of epidemiological
studies and government datasets.
26 As a whole, AF-
related stroke carries a high socioeconomic burden.
Disease management
The goals of AF management are to prevent stroke
with anti-thrombotic therapy (recommended for all
AF patients, except for those with lone AF), symptom
Table 2 Annual stroke risk according to CHADS2
score
17
CHADS2
score
Stroke
risk (%)
95% CI
Low risk 0 1.9 1.2–3.0
Moderate risk 1 2.8 2.0–3.8
2 4.0 3.1–5.1
High risk 3 5.9 4.6–7.3
4 8.5 6.3–11.1
5 12.5 8.2–17.5
6 18.2 10.5–27.4
Adapted with permission from Gage et al.
17 Copyright !
(2001) American Medical Association. All rights reserved.
Table 1 CHADS2 scoring classification
17
Condition Points
C Congestive heart failure 1
H Hypertension: blood pressure consistently
>140/90mmHg (or treated hypertension
on medication)
1
A Age >75 years 1
D Diabetes mellitus 1
S2 Prior stroke or transient ischaemic attack 2
Adapted with permission from Gage et al.
17 Copyright !
(2001) American Medical Association. All rights reserved.
Update on anti-coagulation in atrial fibrillation 749relief and preservation of left ventricular function by
either controlling heart rate or restoring normal sinus
rhythm.
27 The choice between rate or rhythm con-
trol depends upon individual patient characteristics.
The main treatment options for AF are shown in
Figure 1. Anti-coagulation should be continued in
patients at risk of stroke,
27 and is generally recom-
mended even after restoration of normal sinus
rhythm.
Rate and rhythm control
Correction of the underlying arrhythmia in AF may
appear to be the best treatment option. However,
rate control has been shown to be at least as effect-
ive in improving mortality, stroke rate, AF symptoms
and QoL.
28,29 Rate control has also been shown to
be a more cost-effective strategy than rhythm con-
trol, with reduced medical resource requirements.
30
In the emergency setting, the priority is to main-
tain haemodynamic stability by urgently restoring
sinus rhythm or controlling ventricular rate. Direct
current cardioversion should be considered for AF
patients who are haemodynamically unstable, or
who show signs of myocardial ischaemia or heart
failure.
2,31 If AF has presented recently (<7 days)
and the patient is haemodynamically stable, cardio-
version with anti-arrhythmic drugs can be effective.
Class IC agents, such as flecainide or propafenone,
are commonly used in stable AF.
31 If AF has been
present for >48 hours, atrial thrombus must be
excluded and adequate anti-coagulation initiated.
Class IC anti-arrhythmics are not recommended for
elderly AF patients due to the risk of co-morbidities,
such as coronary artery disease or left ventricular
dysfunction. In these patients, and where arrhythmia
has persisted for >1 week, a class III agent, such as
amiodarone may be preferred.
31
Anti-arrhythmic agents vary in their mode of
administration, efficacy in restoring and maintaining
sinus rhythm, and are associated with pro-
arrhythmogenic effects, serious side-effects (Table 3)
and drug–drug interactions. Amiodarone has proven
very effective for maintenance of sinus rhythm after
cardioversion, but its use is limited by side-effects,
including heart disturbances (Table 3).
31 In one trial
in elderly AF patients, the newly introduced agent,
dronedarone, reduced AF recurrence versus pla-
cebo, and also had beneficial effects on cardiovas-
cular mortality/morbidity, although the difference
for all-cause death was statistically non-significant.
Dronedarone therapy also lacked many of the side-
effects associated with amiodarone.
32 Dronedarone
is, however, considered to be less effective than
amiodarone.
Even with a variety of anti-arrhythmic drugs and
repeated external cardioversions, only 39–63% of
AF patients maintain sinus rhythm.
28,29 Rate control
may therefore be a beneficial alternative strategy,
especially in elderly patients. Rate control aims to
achieve a resting heart rate of 60–80 beats/min
(bpm) and avoid periods with an average heart rate
over 1h of >100 bpm. A recent study [RAte Control
Versus Electrical Cardioversion Of Persistent Atrial
Fibrillation (RACE)], however, suggests that resting
heart rates <110 bpm may be equally efficient.
33
Rate control agents include beta-blockers, non-
dihydropyridine calcium antagonists and digoxin,
administered alone or in combination.
The merits of rate versus rhythm control have
been much debated. Rhythm control does not
reduce mortality; the two largest trials of rate
Figure 1. Treatment options in AF
27. Figure adapted from Prystowsky.
27 *Recently licensed in the US, Canada and Japan.
750 J. Kreuzerversus rhythm control suggested that rhythm control
may show a trend towards increased mortality,
28,29
possibly due to anti-arrhythmic drug toxicity or in-
appropriate withdrawal of anti-coagulant therapy.
Patient QoL is similar in rate and rhythm control
groups.
34,35 Rate control is less costly than rhythm
control, involving fewer hospitalizations.
30,36,37
Even using rhythm control strategies, it is common
to prescribe additional rate control drugs,
38 which
can have side-effects including deterioration of left
ventricular function and left atrial enlargement, irre-
spective of rate control.
39
Patients who maintain sinus rhythm have im-
proved long-term prognosis.
40 Newer rhythm con-
trol drugs with advantages over current treatments
may make rhythm control strategies more appealing.
Vernakalant is an atrial-selective, sodium ion and
potassium ion channel blocker approved by the
US Food and Drug Administration (FDA) for intra-
venous conversion of recent-onset AF. Phase II and
III clinical trials have shown efficacy for vernakalant
in stopping AF in 50% of cases vs. 0–10% for pla-
cebo, with very few side-effects. An oral formulation
is currently under assessment in clinical trials; pre-
liminary results suggest that high-dose oral vernaka-
lant prevents AF recurrence without proarrhythmia.
41
Ranolazine, a sodium channel blocker approved for
chronic angina, is also in development for AF; it has
shown safe conversion of new-onset or paroxysmal
AF, and promotion of sinus rhythm maintenance in
two small trials. Other atrial-selective drugs in de-
velopment for AF include several investigational
compounds (e.g. AZD7009, AVE0118, AVE1231),
which have had mixed results.
41
Non-pharmacological ablation techniques for
rhythm control in AF are becoming more popular
and may offer benefits over pharmacotherapy for
some patients. Ablation catheters are inserted trans-
venously into the left atrium and positioned to iso-
late or destroy pulmonary vein foci that may trigger
or maintain AF. Ablation success rates vary depend-
ing on AF type. Curative rates of 80–90% can be
achieved in patients with paroxysmal AF and normal
heart structure; however, success rates are limited in
other cases, such as persistent AF with remodelled
atrial tissue, and success relies upon operator ex-
perience.
42 Furthermore, in rare instances the pro-
cedure may cause life-threatening complications,
such as stroke, pericardial tamponade and atrial–oe-
sophageal fistula. Ablation must therefore be per-
formed by highly trained electrophysiologists at
specialized centres. It is usually reserved for pre-
dominantly younger, symptomatic patients resistant
or intolerant to drug therapies, or for those with
Table 3 Anti-arrhythmic agents for the conversion of AF of up to or more than 7 days duration
2
Agent Class Administration Main adverse effects
Agents with proven efficacy: AF duration47 days only
Flecainide IC Oral or IV Hypotension, atrial flutter with high ventricular rate
Propafenone IC Oral or IV Hypotension, atrial flutter with high ventricular rate
Agents with proven efficacy: AF duration47 days and >7 days
Dofetilide III Oral QT prolongation, torsades de pointes
Ibutilide III IV QT prolongation, torsades de pointes
Amiodarone III Oral or IV Hypotension, bradycardia, QT prolongation, torsades de
pointes (rare), GI upset, constipation, phlebitis (IV)
Dronedarone III Oral Diarrhoea, nausea, abdominal pain, vomiting, asthenia
Less effective or incompletely studied agents
Disopyramide IA IV Dry mouth, constipation, urinary retention, depression of left
ventricular contractility
Procainamide IA IV Hypotension
Quinidine IA Oral QT prolongation, torsades de pointes, GI upset, hypotension
Should not be administered
Digoxin – Oral or IV AV block and increased ventricular ectopy
Sotalol III Oral or IV QT prolongation, torsades de pointes
AV=atrioventricular; GI=gastrointestinal; IV=intravenous.
Adapted from Fuster V et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a
report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the
European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for
the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association
and the Heart Rhythm Society. Europace. 2006; 8 (9):651-745 by permission of the European Society of Cardiology and the
European Heart Rhythm Association.
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more specialized ablation catheters have recently
become available in Europe, which should both
speed up and simplify the ablation process, increas-
ing the number of physicians capable of performing
the procedure.
42 As the understanding of AF patho-
physiology improves, and confidence in the tech-
nique spreads, ablation may become more
widespread.
Less frequently used AF interventions include left
atrial appendage (LAA) closure or removal, which
may aid stroke prevention as >90% of thrombi
form in the left atrial appendage in AF. The
WATCHMAN

device is a self-expanding nitinol
frame with a membrane on the proximal face that
is constrained within a delivery catheter until de-
ployment. It is designed to be permanently im-
planted at, or slightly distal to, the opening of the
LAA to trap potential emboli. Another LAA occluder
under investigation, the AMPLATZER

Cardiac Plug,
has been derived from the AMPLATZER

septal
device.
43 So far, outcome data are only available for
the WATCHMAN

device. The Embolic Protection
in Patients with Atrial Fibrillation (PROTECT–AF)
trial indicated a reduced risk for thromboembolic
events after LAA occlusion.
44
There is a trend towards ‘upstream’ therapy in AF
to target underlying conditions and risk factors.
Statins and suppressors of the rennin–angiotensin
system [e.g. angiotensin-converting enzyme inhibi-
tors (ACEIs)], which prevent atrial remodelling, have
a role to play in AF. Statin therapy prior to ablation
surgery appears to improve post-operative freedom
from paroxysmal and persistent AF in cardiac
surgery patients.
45 ACEIs and angiotensin recep-
tor blockers appear to prevent new AF, reduce
potential recurrence in high-risk individuals and
help prevent AF recurrence following direct current
cardioversion.
46
VKAs for stroke prevention in AF
Anti-coagulation therapy is recommended in add-
ition to rate or rhythm control for the majority of
patients, even for those converted into sinus rhythm.
Current treatment guidelines recommend aspirin or
no treatment for those at low risk of stroke; oral
anti-coagulants, aspirin or VKAs such as warfarin
for patients at moderate risk; and oral anti-
coagulants or VKAs for those at high risk of
stroke.
1,2,47 The 2010 ESC guidelines strongly rec-
ommend oral anti-coagulant therapy over aspirin;
oral anti-coagulant therapy is the treatment of
choice for those at high risk of AF, and is preferred
over aspirin therapy for moderate-risk individuals.
1
Adjusted-dose warfarin is effective for stroke preven-
tion in AF, reducing stroke by 64% [95% confidence
interval (CI) 49–74] and all-cause mortality by 26%
(95% CI 3–43) in a meta-analysis of published ran-
domized trials.
48 However, VKAs carry a consider-
able bleeding risk, making the risk–benefit ratio
inappropriate for patients at lower risk of stroke.
Furthermore, VKAs have limitations including
drug–drug and drug–food interactions, slow onset
and offset of action, and a narrow therapeutic
range, with regular monitoring and dose-adjustment
required.
49 Patients not maintained within the thera-
peutic range are at increased risk of bleeding or
stroke (Figure 2).
50 The greatest concern is increased
risk of intracranial haemorrhage (ICH), which per-
sists even if the optimal INR of 2.0–3.0 is main-
tained, and increases in the presence of other risk
factors including advanced age and high blood
pressure.
51
Achieving good INR control can be challenging.
In well-controlled clinical trials, patients remained
within therapeutic range for 66% of the time,
whereas in clinical practice only 44% of time
was spent within the therapeutic range.
52–54 Such
challenges have led to the under-use of VKAs,
which has been associated with adverse out-
comes.
55 An assessment of Medicare claims data
for 1993–1996 showed that only 55% of eligible
patients were prescribed anti-thrombotic therapy at
hospital discharge, with 34% receiving warfarin.
55 A
cross-sectional study of a large health maintenance
organization (1996–1997) showed that warfarin was
used in only 55% of 11 082 eligible patients.
56
Thus, novel anti-coagulants that are more effica-
cious and have better safety profiles are needed.
Developments in stroke prevention
in AF
Several novel anti-coagulants targeting different
components of the coagulation cascade are being
trialled for stroke prevention (Figure 3, Table 4).
57
Dabigatran etexilate
Dabigatran etexilate is an oral pro-drug, metabo-
lized to the potent direct thrombin inhibitor (DTI)
dabigatran. It is licensed in over 70 countries for
thromboprophylaxis following total elective hip
and knee replacement,
58 and is the newest anti-
coagulant licensed for stroke prevention in AF in
Canada and for reduction of risk of stroke in the
USA.
59,60 The Randomized Evaluation of Long-
Term Anticoagulant Therapy (RE-LY

) trial, one of
the largest AF outcomes trials completed to date,
752 J. Kreuzercompared two doses of dabigatran etexilate (150mg
twice daily [bid] and 110mg bid) with warfarin (INR
2.0–3.0) in patients with AF and at least one add-
itional risk factor for stroke.
61 The study included
18113 patients randomized at 951 centres in
44 countries.
62 The primary endpoint was the com-
posite of stroke (haemorrhagic and ischaemic) and
non-CNS systemic emboli.
In AF patients at risk of stroke (50% warfarin-
experienced and 50% warfarin-naive), 150mg dabi-
gatran etexilate bid was significantly more effective
than well controlled warfarin for stroke prevention
[1.11% per year vs. 1.71%, hazard ratio (HR) 0.65,
95% CI 0.52–0.81, P<0.001] and vascular death
(2.28% per year vs. 2.69%, HR 0.85, 95% CI
0.72–0.99, P=0.04) with a similar risk of major
bleeding. However, rates of total and life-
threatening bleeding were both significantly lower
with 150mg bid dabigatran etexilate than with war-
farin.
63 Importantly, VKAs are effective in preventing
64% of all strokes,
48 whereas in the RE-LY

study,
dabigatran etexilate (150mg bid) further reduced the
risk of stroke or systemic emboli by an additional
35% (RRR) compared with well-controlled war-
farin.
63 Compared with no anti-coagulant treatment
in patients with AF, three out of four strokes may be
prevented by dabigatran etexilate 150mg bid.
64
Furthermore, dabigatran etexilate 110mg bid
Figure 2. Narrow therapeutic range with VKA.
50 Reproduced with permission from Singer et al.
50
Figure 3. Coagulation cascade targets for novel anti-coagulants. Adapted from Bates and Weitz.
57 Copyright ! 2006, John
Wiley and Sons. Reproduced with permission of Blackwell Publishing Ltd.
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warfarin, with significantly lower rates of major
bleeding (2.87% vs. 3.57% per year, HR 0.80,
95% CI 0.70–0.93, P=0.003) and other bleeding
events.
63
Rates of haemorrhagic stroke and ICH (composite
of haemorrhagic stroke, subarachnoid haemorrhage
and subdural haematoma) were significantly lower
in patients taking either dose of dabigatran etexilate
than in individuals taking warfarin. Rates of haem-
orrhagic stroke were 0.38% in the warfarin group,
0.10% (HR 0.26, 95% CI 0.14–0.49, P<0.001) in
the 150mg dabigatran etexilate group and 0.12%
(HR 0.31, 95% CI 0.17–0.56, P<0.001) in the
110mg dabigatran etexilate group. Respective
rates of ICH were 0.76% for warfarin, 0.32%
Table 4 Novel anti-coagulants for stroke prevention in AF
Compound
name
Mechanism of action Trial efficacy outcomes Adverse outcomes
Dabigatran
etexilate
Direct thrombin
inhibitor
RELY

trial: 150mg bid more
effective and 110mg bid similarly
effective versus warfarin for stroke
prevention in patients with AF and
51 additional risk factor
63
150mg bid similar major
bleeding and 110mg bid
lower major bleeding versus
warfarin. Both doses had lower
haemorrhagic stroke and ICH
versus warfarin
AZD0837
Development
discontinued
July 2010
Direct thrombin in-
hibitor (extended
release formulation)
300mg qd similar thrombogenesis
(D-dimer) suppression to warfarin
69
Lower clinically relevant bleeding
rates
69
Apixaban Direct FXa inhibitor ARISTOTLE trial: versus warfarin
in patients with AF and 51 add-
itional risk factor; ongoing (results
expected in 2011)
71
AVERROES trial: more effective
versus aspirin for stroke prevention
in patients with AF and 51 add-
itional risk factor considered un-
suitable for warfarin
73
Similar major bleeding rate to
aspirin
73
Rivaroxaban Direct FXa inhibitor ROCKET-AF trial: non-inferior versus
warfarin in the ITT analysis for
stroke/non-CNS embolism in
non-valvular AF with prior stroke/
TIA or two additional stroke risk
factors
75 Lower ICH incidence
versus warfarin
76,77
Similar rates of major and
non-major bleeding as
warfarin
75
Edoxaban
(DU-176b)
Direct FXa inhibitor ENGAGE-AF TIMI-48 trial ongoing
(2008-2012) of 30/60mg qd versus
warfarin for AF with moderate
stroke risk
79
Phase II trial: 30/60mg qd similar
safety profile to warfarin in
CHADS2 52; 30/60mg bid
more bleeding events
78
Betrixaban Direct FXa inhibitor EXPLORE-Xa trial: 40mg qd better
coagulation activity (measured by
D-dimer levels) versus warfarin
83
40mg qd fewer major and
non-major bleeds versus
warfarin. 60/80mg more
frequent nausea, vomiting and
diarrhoea
83
Tecarfarin Vitamin K antagonist Phase II trial versus warfarin showed
improved time in therapeutic
range
84
EmbraceAC trial: comparable with
warfarin for time in therapeutic
range
85
AF; atrial fibrillation; bid=twice daily; CNS=central nervous system; ICH=composite of haemorrhagic stroke, subarachnoid
haemorrhage and subdural haematoma; qd=once daily; TIA=transient ischaemic attack.
754 J. Kreuzer(HR 0.41, 95% CI 0.28–0.60, P<0.001; 150mg
dabigatran etexilate) and 0.23% (HR 0.30, 95% CI
0.19–0.45, P<0.001; 110mg dabigatran
etexilate).
63
Dabigatran etexilate was generally well tolerated,
with reported adverse event rates similar to those
reported with the use of warfarin. Dyspepsia
occurred more frequently for both doses of dabiga-
tran etexilate than with warfarin (150mg dabigatran
etexilate, 11.3% and 110mg dabigatran etexilate,
11.8% versus warfarin, 5.8%; P<0.001 for both
comparisons).
62 Dyspepsia may be manageable by
taking dabigatran etexilate with food, with the use of
antacids and/or administration of proton pump in-
hibitors. In addition, the higher dose of dabigatran
etexilate was associated with a higher risk of gastro-
intestinal bleeding than with either the lower dose or
warfarin (1.56% per year for 150mg dabigatran
etexilate vs. 1.15% per year for 110mg dabigatran
etexilate, and 1.07% per year for warfarin, P=0.001
for the comparison of 150mg dabigatran and war-
farin,P=0.52 for the comparison of 110mg dabiga-
tran and warfarin).
63 The incidence of myocardial
infarction was numerically higher with dabigatran
etexilate than with warfarin, but this imbalance
did not reach statistical significance. Neither dose
of dabigatran etexilate appeared to cause liver
toxicity.
62
Dabigatran etexilate possesses other benefits
compared with warfarin therapy. It has a rapid
onset and offset of action, and a predictable and
consistent pharmacodynamic profile.
65,66 The elim-
ination half-life of dabigatran etexilate is 12–17h,
which allows for twice-daily dosing.
62 Due to a
more consistent and predictable anti-coagulant
effect there is no requirement for routine anti-
coagulation monitoring.
66 Finally, dabigatran etexi-
late has a low potential for drug–drug interactions;
has no food–drug interactions; and does not interact
with the cytochrome 450 (CYP450) enzyme
system.
67,68 Based on these improvements including
superior efficacy of the 150mg dose relative to war-
farin, the predictability and consistency of its phar-
macokinetic and anticoagulant activity, dabigatran
etexilate has the potential to replace much of the use
of warfarin and other oral VKAs for stroke preven-
tion in patients with AF. In addition, the availability
of two doses (75mg bid and 150mg bid in the USA,
and 110mg and 150mg bid in Canada) allows a
lower dose to be used in vulnerable patient
groups. For example, in the USA, 75mg bid can
be used in patients with a creatinine clearance of
15–30ml/min, while in Canada, 110mg bid may be
suitable for use in patients 580 years and/or at risk
of bleeding.
59,60
AZD0837
AZD0837 is another pro-drug, which is converted to
a selective and reversible DTI. The safety of an
extended-release formulation has been assessed in
a phase II, randomized, controlled trial.
69 Nine hun-
dred and fifty-five patients with AF were randomized
to receive AZD0837 150mg once daily (qd),
300mg qd, 450mg qd or 200mg bid, or warfarin
(INR 2.0–3.0), for 3–9 months. AZD0837 300mg qd
provided similar thrombogenic suppression to war-
farin with lower bleeding rates (any bleeding: 5.3%
vs. 14.5%; clinically relevant bleeding: 0% vs. 2.8%
for AZD0837 and warfarin, respectively with no
liver toxicity. A 10% increase in serum creatinine
was observed, which returned to baseline after ces-
sation of therapy.
69 As of July 2010, however, the
development of AZD0837 had been discontinued
by the manufacturer.
70
Apixaban
Apixaban is a direct factor Xa inhibitor that prevents
conversion of prothrombin to thrombin. Apixaban is
under investigation for thrombolic and haemorrhagic
events compared with warfarin (INR 2.0–3.0) in the
Apixaban for the Prevention of Stroke in Subjects
With Atrial Fibrillation (ARISTOTLE) trial, an inter-
national, double-blind, randomized, non-inferiority
trial of 18206 AF patients with at least one add-
itional risk factor for stroke.
71 In this trial, 5.0mg is
the standard apixaban dose, however, 2.5mg will
be used in patients estimated to have higher apixa-
ban exposure. A similar randomized, double-blind,
superiority trial comparing 5mg apixaban bid with
aspirin (81–324mg qd) for prevention of stroke or
systemic embolism in 55600 patients with AF and
at least one risk factor for stroke has recently been
completed [the Apixaban Versus Acetylsalicylic
acid to Prevent Strokes (AVERROES) trial].
72,73 This
study was terminated prematurely after the first in-
terim efficacy analysis and the results showed
an incidence of stroke of 1.6% per year with apix-
aban, vs. 3.7% per year with aspirin (apixaban
HR 0.45, 95% CI 0.32–0.62, P<0.001); both treat-
ments were associated with similar rates of major
bleeding (1.4% per year with apixaban vs. 1.2%
with aspirin; apixaban HR 1.13, 95% CI
0.74–1.75, P=0.57).
73
Rivaroxaban
Rivaroxaban, another factor Xa inhibitor, is being
tested in several indications and is currently licensed
for thromboprophylaxis following elective total hip
and knee replacement.
74 A Phase III, randomized,
double-blind, non-inferiority study (ROCKET-AF
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aban versus warfarin to prevent stroke in non-
valvular AF patients with prior stroke/TIA or at
least two additional stroke risk factors
75, has re-
cently completed. In this trial, which included over
14000 patients, rivaroxaban was non-inferior
(P<0.001) to dose-adjusted warfarin for the primary
endpoint; a composite of stroke and non-central ner-
vous system embolism. For this endpoint, rivaroxa-
ban provided a relative risk reduction of 21% over
warfarin (P=0.015) in the on-treatment analysis;
however, in the intention-to-treat analysis, rivaroxa-
ban failed to demonstrate superiority (P=0.117).
Both rivaroxaban and warfarin were associated
with similar rates of major and non-major bleeding
(P=0.442). The incidence of ICH was significantly
lower in subjects taking rivaroxaban than in individ-
uals receiving warfarin (P=0.019).
76,77
Edoxaban
A multicentre, Phase II study was conducted to in-
vestigate the safety of the factor Xa inhibitor edox-
aban (DU-176b) in AF patients with a CHADS2
score 52. In total, 1146 patients were randomized
to blinded edoxaban (30mg qd, 60mg qd, 30mg
bid or 60mg bid) or open-label warfarin (INR
2.0–3.0) for 3 months. Results indicate that 30 and
60mg qd edoxaban had a similar safety profile
to warfarin, whereas the 30 and 60mg bid groups
experienced more bleeding events than those
receiving warfarin.
78 A phase III, randomized,
double-blind trial [Effective aNticoaGulation with
factor xA next GEneration in Atrial Fibrillation
(ENGAGE-AF TIMI-48)] is now currently assessing
the safety and efficacy of 30 and 60mg qd edoxa-
ban compared with warfarin in patients with AF and
a moderate risk of stroke.
79
Betrixaban
Another factor Xa inhibitor, betrixaban, was selected
from a promising range of investigational com-
pounds in early development.
80 The anticoagulant
effects of betrixaban in humans was initially inves-
tigated in the US and Canadian trial, in which it
was compared with enoxaparin for prevention of
thromboembolism after knee replacement surgery
[the Evaluation of betriXaban for the Prevention of
vEnous thRomboembolism in daily practice
(EXPERT) trial].
81 In this study, 215 patients were
randomized to treatment with betrixaban 15mg or
40mg bid, or enoxaparin 30mg subcutaneously
every 12h for 10–14 days. Betrixaban inhibited
thrombin generation and anti-Xa levels in a dose-
and concentration-dependent manner and was
well tolerated, with no indication of increased
bleeding events.
A Phase II trial of the safety, tolerability and pilot
efficacy of daily oral 40, 60 or 80mg doses of betrix-
aban versus warfarin for anti-coagulation in AF pa-
tients has recently been completed (EXPLORE-Xa).
82
Betrixaban 40mg had fewer instances of major and
clinically relevant non-major bleeding compared
with patients taking warfarin (1 vs. 4 patients) and
slightly better coagulation activity (as measured by
D-dimer levels). Nausea, vomiting and diarrhoea
were the only adverse events that occurred more
frequently in the betrixaban than in warfarin pa-
tients, and occurred only in patients taking the
60mg and 80mg doses.
83
Tecarfarin
Tecarfarin is an oral VKA similar to warfarin, but is
reportedly metabolized by esterases rather than
the CYP450 system, thereby potentially avoiding
CYP450-mediated drug–drug or drug–food inter-
actions. A 6- to 12-week, open-label, multicentre,
Phase II trial of tecarfarin versus warfarin in 66 AF
patients showed that tecarfarin improved patient
time in the therapeutic range.
84 A recent phase
II/III, randomized, double-blind, parallel-group,
active-control study (EmbraceAC) involving 612 pa-
tients in the USA, treated with either tecarfarin or
warfarin, showed that both achieved comparable
patient times in therapeutic range (74.0% vs.
73.2%, respectively, P=0.506); the primary end-
point of the trial (superiority of tecarfarin over war-
farin) was therefore not attained.
85
While many novel anti-coagulants are currently in
development and undergoing clinical trials, dabiga-
tran etexilate 150mg bid has been proven to have
superior efficacy to well-controlled warfarin for
stroke prevention in AF in a phase III study. It was
approved by the FDA and Health Canada in
October 2010. We await results from recently com-
pleted or ongoing trials of other anti-thrombotic
agents.
Conclusions
AF is associated with a pro-thrombotic state and sev-
eral other comorbidities that increase the risk of
stroke in an age-dependent fashion. Rate and
rhythm control are employed to relieve the symp-
toms of AF; however, anti-arrhythmic drugs are fairly
toxic and have variable efficacy. Rate control is
easier to manage and has equivalent mortality and
QoL outcomes to rhythm control; thus the debate
continues as to which therapy is preferable.
Rhythm control using non-pharmacological ablation
756 J. Kreuzertechniques has thus far been limited because of the
need for specialist centres and highly trained oper-
ators. However, the advent of improved ablation
catheters and increased understanding of AF patho-
physiology should enhance confidence in perform-
ing this technique.
Anti-coagulation therapy is an essential strategy in
AF patients with additional stroke risk factors and
can decrease the incidence of stroke and mortality
in AF patients. However, warfarin is under-used be-
cause of a high perceived risk of haemorrhage (es-
pecially ICH) and limitations that make the drug
difficult to manage. Dabigatran etexilate is a novel
DTI offering improvements in efficacy and safety
compared with warfarin for stroke prevention in
AF. In addition, several other novel anti-coagulants
in development show promise, and their efficacy
and safety are currently being evaluated in the pre-
vention of stroke in AF patients. New therapeutic
options, such as improved anti-arrhythmics, novel
anti-coagulants and more accessible ablation tech-
niques are likely to deliver better care for AF patients
in the near future.
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